期刊文献+

单中心687例软组织肉瘤临床病理统计分析 被引量:10

Analysis of clinical and pathological characteristics of 687 soft tissue sarcoma cases in a single sarcoma centre
下载PDF
导出
摘要 目的 探讨中国人软组织肉瘤(soft tissue sarcoma,STS)的临床特点、发病趋势及病理亚型,为制定软组织肉瘤的规范化治疗指南提供依据。方法 对北京大学肿瘤医院骨与软组织肿瘤科在2007年7月至2013年11月间收治的687例软组织肉瘤患者的临床及病理资料进行回顾性研究。结果收治的软组织肉瘤患者以肢体占绝大多数,其中男性430例,女性257例。男女发病比例约1.67∶1。发病年龄在4~84岁之间,平均发病年龄45.6岁,中位发病年龄45岁。常见的软组织肉瘤包括恶性纤维组织细胞瘤/高级别多形性未分化肉瘤(20.52%),脂肪肉瘤(18.63%),皮肤隆突性纤维肉瘤(14.26%),滑膜肉瘤(11.35%),纤维肉瘤(8.01%)等。STS好发部位依次为下肢、躯干、上肢、肩部、胸壁、臀部、腹壁、头颈等处。结论 STS临床及病理表现复杂,治疗效果差。而受发病率低等因素的制约,国内对STS的大样本量研究较少,应尽快开展多中心大样本的研究。 Objective This study is to discuss the clinical characteristics,incidence trend and pathological subtypes of Chinese sarcoma patients,and provide evidence to the standard treatment guidelines of the soft tissue sarcomas. Methods 687 STS patients were treated in department of bone and soft tissue tumor of Peking University Cancer Hospital from July,2007 to November,2013. The clinical and pathological data were under retrospective analysis. Results Most patients were of extremity soft tissue sarcomas. There were 430 male,257 female; the male-female ratio is 1. 67 ∶ 1. The onset age is between 4-84 years,the average onset age is45. 6,the mean onset age is 45. The more common sarcoma subtypes include malignant fibrous histiocytoma( MFH) /high level pleomorphic undifferentiated sarcoma( 20. 52%),liposarcoma( 18. 63%),dermatofibrosarcoma protuberans( 14. 26%),synovial sarcoma( 11. 35%),fibrosarcoma( 8. 01%). The predilection sites of STS are lower limbs,trunk,upper limbs,shoulders,chest wall,hips,abdominal wall,head and neck.Conclusions STS is of complex clinical and pathological performance,with poor treatment outcome. Because of the very low morbidity,there is little large sample study of STS in China,so the multi-center large sample study should be given consideration as soon as possible.
出处 《中国肿瘤外科杂志》 CAS 2015年第1期6-8,13,共4页 Chinese Journal of Surgical Oncology
关键词 软组织肉瘤 流行病学 病理学 soft tissue sarcoma epidemiology pathology
  • 相关文献

参考文献9

  • 1NCCN Guidelines Version 1. 2013 Soft Tissue Sarcoma.
  • 2Gutierrez JC, Perez EA, Franceschi D, et al. Outcomes for soft- tissue sarcoma in 8249 cases from a large state cancer registry[ J]. J Surg Res,2007, 141 ( 1 ) :105-114.
  • 3Toro JR,Travis LB, Wu H J, et al. Incidence patterns of soft tissue sarcomas, regardless of primary site, in the surveillance, epidemi- ology and end results program, 1978-2001 :An analysis of 26,758 cases[J]. Int J Cancer, 2006, 119(12) :2922-2930.
  • 4Sherman KL, Wayne JD, Chung J, et al. Assessment of multimo- dality therapy use for extremity sarcoma in the United States [ J ]. J Surg Onco1,2014,109 (5) :395-404.
  • 5中山医学院病理教研组,2666例软组织肿瘤病理活检统计分析[J],肿瘤防治研究,1978,(2):30-34.
  • 6赖日权,王卓才,戈立东,陈炳旭,霍铮.1434例软组织恶性肿瘤统计分析[J].诊断病理学杂志,1998,5(4):201-203. 被引量:12
  • 7方志伟,滕胜,陈勇,薛瑞峰,陈静.软组织肉瘤1118例临床病理分析[J].中华肿瘤防治杂志,2009,16(4):305-307. 被引量:19
  • 8薛卫成、方志伟.软组织肿瘤[M].5版.北京:北京大学医学出版社,2011:403.
  • 9Garbay D, Maki RG, Blay JY, et al. Advanced soft-tissue sarco- ma in elderly patients: patterns of care and survival [ J]. Ann On- col, 2013, 24(7) : 1924-1930.

二级参考文献14

  • 1张学斌,陈高平.1021例软组织肉瘤的病理活检统计分析[J].西安医科大学学报,1993,14(4):383-386. 被引量:14
  • 2赖日权,熊敏,安建成,田野,季卉,李雯.多形性横纹肌肉瘤的鉴别诊断[J].诊断病理学杂志,1995,2(2):79-81. 被引量:4
  • 3Lazar A, Abruzzo L V, Pollock R E, et al. Molecular diagnosis of sarcomas: chromosomal translocations in sarcomas[J].Arch Pathol Lab Med, 2006, 130(8) :1199-1207.
  • 4Rapheal E. Pollock, Atlas of clinical oncology, soft tissue sarcomas[M]. Philadelphia: BC Decker: American Cancer Society, 2002:1-8.
  • 5Gutierrez J C, Perez E A, Franceschi D, et al. Outcomes for soft tissue sarcoma in 8249 cases from a large state cancer registry[J].J Surg Res, 2007, 141(1) :105-114.
  • 6冯传汉,张铁良.临床骨科学[M].2版.北京:人民卫生出版社,2004:3558-3584.
  • 7Nakayama R, Nemoto T, Takahashi H, et al. Gene expression analysis of soft tissue sarcomas: eharacterlzation and reclassification of malignant fibrous histiocytoma[J].Mod Pathol, 2007, 20(7):749-759.
  • 8Toro J R,Travis L B,Wu H J,et al. Incidence patterns of soft tissue sarcomas, regardless of primary site,in the surveillance, epidemiology and end results program, 1978-2001:An analysis of 26,758 cases[J]. Int J Cancer, 2006, 119(12):2922-2930.
  • 9Letson G D. Soft tissue sarcoma: status in 2005[J]. Cancer Control, 2005, 12(1): 2.
  • 10Fang Z, Matsumoto S, Ac K, et al. Postradiation soft tissue sarcoma: a multiinstitutional analysis of 14 cases in Japan[J].J Orthop Sci,2004,9(3) :242-246.

共引文献28

同被引文献53

  • 1李恩孝,张雅婷,尚金堂,许真,耿熠,李署明,施璠,吴胤瑛.改良MAID方案治疗54例晚期软组织肉瘤的疗效分析[J].癌症,2006,25(8):1048-1051. 被引量:4
  • 2张薇.软组织肉瘤声像图改变与病理关系的探讨[J].中国社区医师(医学专业),2007,9(18):88-89. 被引量:1
  • 3黄红兵,林桐榆.肿瘤治疗止吐药物临床应用研究进展[J].中华肿瘤防治杂志,2007,14(21):1675-1678. 被引量:12
  • 4Fang ZW, Chen J, Teng S,et al. Analysis of soft tissue sarco- mas in 1 118 casesFJ. Chin Med J (Engl), 2009,122: 51-53.
  • 5OByrne K,Steward WP. The role of chemotherapy in the treatment of adult soft tissue sarcomas [J]. Oncol, 1999, 56 (1) 13-23.
  • 6Zucali PA,Bertuzzi A, Parra H J, et al. The"old drug" dacarba- zine as a second/third line chemotherapy in advanced soft tissue sarcomas[J]. Invest New Drugs,2008, 26(2) :175-181.
  • 7Wicha MS, Liu S, Dontu G. Cancer stem cellsan old idea- para- digm shift [J]. Cancer Res, 2006, 66(4).1883.
  • 8Yamamoto N, Sekine I, Nakagawa K, et al. A pharmacokinetic and dose escalation study of peg-lgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia[J]. Jpn J Clin 0ncol,2009,39(7) :425-430.
  • 9Chan A, Leng XZ, Chiang JY, et al. Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients[J]. Asia Pac J Clin Oncol,2011,7(1) :75-81.
  • 10Klastersky J, Awada A. Prevention of febrile neutropenia in chemotherapy-treated cancer patients: pegylated versus standard myeloid colony stimulating factors. Do we have a choice? [J]. Crit Rev Oncol Hematol,2011,78(1) : 17-23.

引证文献10

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部